Negotiations Involving the Central Labor Office Under Consideration

Early Talks Sought Ahead of Next Month's Follow-Up Mediation

The labor and management at Samsung BioLogics, which have been unable to resolve their strike for four months, have reached a consensus to conclude negotiations before the upcoming Chuseok holiday and are focusing on accelerating the pace of talks.


Aerial view of Samsung BioLogics Plant 4 in Songdo, Incheon. Samsung BioLogics

Aerial view of Samsung BioLogics Plant 4 in Songdo, Incheon. Samsung BioLogics

View original image

According to government and labor sector sources on August 27, Samsung BioLogics' labor and management have agreed to pursue a separate dialogue, with participation from the Central Regional Employment and Labor Office, at an earlier date than the post-mediation negotiations expected to be held at the Incheon Regional Labor Relations Commission (Incheon Labor Commission) in mid-September. This agreement appears to stem from the judgment on both sides that it is no longer possible to leave the prolonged production disruption unattended.


If the Central Regional Employment and Labor Office decides to intervene, a negotiation session will be arranged with one mediator from the Incheon Labor Commission and an official from the Central Regional Employment and Labor Office participating together. Unlike the official post-settlement process, which requires coordination of the schedules of all mediators, this approach allows for a more flexible and expedited timetable. For this reason, it is anticipated that the talks between labor and management may gain momentum. Labor and management are also holding their 27th autonomous negotiation session on this day, just two weeks after the previous round of talks.


[Exclusive] Will Samsung Biologics Strike End Before Chuseok... Labor Ministry Steps In To Mediate View original image

A simplified round-table negotiation with the Central Regional Employment and Labor Office was already convened in May, but it ended without any tangible results. At that time, the union demanded an average wage increase of 14%, a KRW 30 million incentive per person, and a performance bonus equivalent to 20% of annual operating profit. The management offered a 6.2% wage increase and a one-time payment of KRW 6 million, seeking to find common ground, but the talks fell through. Disagreements were also substantial regarding union pre-approval rights for new hires, personnel evaluations, and mergers and acquisitions (M&A).


Meanwhile, there are reports from inside and outside the company that the gap between both sides regarding the extent of wage increases, which is a key issue, has recently narrowed to some extent. Previously, the union cited differences in annual contract salaries with competing companies as grounds for seeking a greater increase. The difference in contractual annual salary between Samsung BioLogics and the competitor specified by the union is said to be about 15%. It is also reported that the management agreed with the principle that the company should maintain a competitive edge in wages.



In the first half of this year, Samsung BioLogics recorded consolidated sales of KRW 2.578 trillion and operating profit of KRW 1.1672 trillion, representing year-on-year increases of 28.0% and 28.6%, respectively. Even in the second quarter, which included the full-scale strike, the company posted record-high quarterly sales of KRW 1.3209 trillion and operating profit of KRW 586.4 billion. However, the plant utilization rate in the first half dropped to 69.9%, compared to 70.9% last year and 75.2% in 2024. Given the nature of the business, it is expected that much of the impact of the strike will be reflected in performance during the second half of the year. A Samsung BioLogics official stated, "We will continue to engage in negotiations in good faith."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing